DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Alzheimers/Neurology Homepage

MR shows promise for predicting neurological outcomes in cardiac arrest survivors May also help develop therapies

New research finds brain MR study groups don't reflect U.S. population demographics This must change for large, multicenter studies

Siemens gets 7T MR cleared for clinical use in U.S. MAGNETOM Terra offers benefits for neuro and MSK imaging

Leica Microsystems showcased new vascular fluorescence imaging modality at CNS meeting All data on single augmented platform

MR detects neurological impairments in newborns with CHD before surgery Detects brain impairments even before cardiac surgery

Olympus to launch 4K-3-D Microscope at Congress of Neurological Surgeons Allows entire surgical team to monitor operation in progress

Brainlab scores FDA clearance for two new radiosurgery software applications Plans spine and brain procedures

PET imaging used for the first time to evaluate Zika virus in mouse model May aid in development of therapeutic agents

New guidelines advise against the use of brain imaging to diagnose chronic pain Researchers continue to look for brain-based biomarkers

FDA approves sale of SyMRI IMAGE software for GE Healthcare MR scanners Reduces scan times

Helen Jenkins

Alkahest appoints new chief operating officer
August 07, 2017
SAN CARLOS, Calif., Aug. 7, 2017 /PRNewswire/ -- Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative diseases and other age-related conditions, announced today that Helen Jenkins has joined the company's executive team as Chief Operating Officer. In this role, Ms. Jenkins will be responsible for translating corporate business priorities into operational tactics that achieve Alkahest's financial and strategic goals.

Ms. Jenkins joins Alkahest from Tobira Therapeutics, Inc. where she served as Chief Operating Officer, and played a key role in Tobira's acquisition by Allergan plc in a deal valued at up to $1.7 billion in November of 2016.

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



"Helen is an outstanding drug developer with an excellent track record of industry leadership," said Dr. Karoly Nikolich, Co-Founder, Chairman and CEO of Alkahest. "Helen brings extensive product development and management expertise to Alkahest and shares our dedication to discover and develop effective therapies for neurodegenerative diseases."

"I am thrilled to join Alkahest's leadership team, and to participate in the progression of the Company's preclinical and clinical stage pipeline. We are entering into an unprecedented period of productivity in the development of therapies for age-related diseases, and it's exciting to be at the forefront," said Ms. Jenkins.

Ms. Jenkins brings nearly 30 years of drug development experience in biotechnology to Alkahest, highlighted by a strong understanding of science, drug development, project management and regulatory requirements. Before serving in multiple roles of increasing responsibility at Tobira, Helen served as a corporate officer at Nuon Therapeutics, Inc. and Saegis Pharmaceuticals, where she was responsible for development operations, strategic planning and portfolio management. Prior to Nuon and Saegis, Ms. Jenkins was Senior Director, Product Development/Regulatory Affairs, at Valentis, Inc., and she previously led preclinical programs through successful IND filings during her tenures at Glycomed Inc. and Genentech, Inc. Ms. Jenkins has a Masters of Arts in cellular and molecular biology from San Francisco State University, San Francisco, CA.

About Alkahest
Alkahest is developing treatments for age-related diseases, with an emphasis on cognitive dysfunction and dementia -- key medical challenges of our generation. The company's breakthrough research has demonstrated that factors in blood plasma of young animals are able to reverse brain deficits in normal aging and Alzheimer's disease models in animals. Alkahest is a clinical-stage private company based in San Carlos, CA, with investors including Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies, as well as a collaboration and commercialization partner. For further information, see www.alkahest.com.

SOURCE Alkahest, Inc.

Alzheimers/Neurology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED